Previous studies from our group had identified c-myc oncoprotein expression as an important prognostic parameter in a series of retrospective studies of primary and metastatic melanoma and other variants of this disease. This study set out to prospectively evaluate the prognostic significance of c-myc positivity in a consecutive series of primary melanomas presenting at Mount Vernon Hospital Regional Plastic Surgery and Burns Centre.
A consecutive series of 117 primary melanomas underwent flow cytometric analysis for c-myc expression at diagnosis. Routine clinical and histological parameters were collected from each patient's clinical records and survival assessed. The mean follow up was 45 months.
Kaplan–Meier survival analysis demonstrated that Breslow depth, histogenic subtype, ulceration, age and sex had prognostic significance. Survival analysis revealed high c-myc positivity to be significantly associated with poorer outcome (P<0.043). Each of the main prognostic parameters were assessed for their independent significance using Cox Proportional Hazards; only c-myc retained independent significance (P<0.039).
The strength of this study is that it was performed in a consecutive series of patients followed up in a longitudinal prospective study. c-myc was not the strongest predictor of survival in univariate analysis, but was the only parameter that retained significance in multivariate analysis.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Plastic, Reconstructive & Aesthetic Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system.J Clin Oncol. 2001; 19: 3622-3634
- The prognostic and therapeutic significance of c-myc expression in melanoma.University College London, 1998
- The clinical significance of c-myc oncogene expression in melanomas of the scalp.Br J Plast Surg. 1998; 51: 191-194
- An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma.Br J Plast Surg. 2000; 53: 46-50
- The c-myc oncogene: use of a biological prognostic marker as a potential target for gene therapy in melanoma.Br J Plast Surg. 2002; 55: 623-627
- The clinical significance of oncogene expression in subungual melanoma.Br J Plast Surg. 1997; 50: 15-19
- Use of oncogene expression as an independent prognostic marker for primary melanoma.Ann Plast Surg. 2003; 50: 183-187
- Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.Br J Plast Surg. 1999; 52: 122-126
- Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma.Br J Plast Surg. 1997; 50: 478-482
- Lethal ‘thin’ malignant melanoma. Identifying patients at risk.Ann Surg. 1988; 208: 150-161
- Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.J Histochem Cytochem. 1983; 31: 1333-1335
- The prognostic importance of c-myc oncogene expression in head and neck melanoma.Ann Plast Surg. 2001; 47: 172-177
Published online: January 31, 2007
Accepted: November 9, 2006
Received: May 15, 2006
☆Work presented at BAPS Scientific Meeting, Dublin, July 2004.
© 2006 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Inc. All rights reserved.